We operationalized and validated the LANS criteria by tying limbic degeneration to an older age at evaluation, mild clinical syndrome, disproportionate hippocampal atrophy according to clinical severity, limbic hypometabolism, absence of neocortical degenerative disease pattern and low likelihood of neocortical tau. This evidence concerns the gene MAPT and hippocampal atrophy.